License, Collaborative and Employment Agreements and Commitments (Details Textual) (USD $)	12 Months Ended			1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 29, 2012	Dec. 31, 2011
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research and Development Expense	$ 14,489,000	$ 6,507,000	$ 12,287,000
Operating Leases, Rent Expense	77,000	68,000	123,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,382,500	222,500	2,075,000
Registration Payment Arrangement, Term			In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a resale registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance.
Prepaid Expense and Other Assets, Current	1,548,000	1,591,000
Payments to Acquire in Process Research and Development	293,000	1,000,000	87,000
Exchange percentage of unregistered common stock	50.00%
Proceeds from (Repurchase of) Equity, Total	3,000,000
Mark Pimentel [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Common stock Outstanding Percentage	8.50%
Licensing Agreements [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Payments for Fees	150,000
Stock Issued During Period, Shares, New Issues	291,569
Patents [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Payments for Fees	220,000
Jeffrey Riley [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				1,700,000
Officers Compensation				348,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				750,000
C. Evan Ballantyne [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				1,000,000
Officers Compensation				298,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				425,000
Intrexon [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research and Development Expense			7,800,000
Partial Consideration for Execution					Intrexon a number of shares of our common stock equal to 9.995% of the number of shares of the Companys common stock issued
Stock Issued During Period, Shares, Acquisitions			3,552,210
Development Stage Entities, Equity Issuance, Per Share Amount			$ 0.001		$ 0.001
Prepaid Expense and Other Assets, Current	2,500,000
Intrexon [Member] | Research and Development Arrangement [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Prepaid Expense and Other Assets, Current	1,100,000
Prev Abr Llc [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Additional Cash Payment for License Agreement			235,000
Unregistered Shares Issued to License Agreement			625,000
Additional Consideration Payable			50% in cash and 50% in our stock
Options To Be Received Common Stock Shares	212,843
Cedars-Sinai Medical Center [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Common stock Outstanding Percentage	11.50%
Office Space In Ann Arbor [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Lease Leasing Term			extend the term of the lease to December 31, 2015
Operating Leases, Future Minimum Payments Due, Next Twelve Months			35,000
Office Space In Rockville [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Lease Leasing Term			one year operating lease that may be renewed for two additional terms of one year
Operating Leases, Future Minimum Payments Due, Next Twelve Months			42,000
December 31, 2014 [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months			50,000
December 31, 2015 [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months			25,000
Phase I Clinical Trials [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment			50,000
Phase Iii Clinical Trials [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment			100,000
Nda Submission In Us [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment			250,000
European Medicines Agency Approval [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment			100,000
Regulatory Approval In Asian Country [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Milestone Payment			100,000
IND Milestone Event [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Registration Payment Arrangement, Settlement Alternatives			The Company also agreed upon the filing of an IND application with the FDA for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the IND Milestone Event), to pay Intrexon either (i) $2.0 million in cash, or (ii) that number of shares of Common Stock (the IND Milestone Shares) having a fair market value equaling $2.0 million where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event.
Approval Milestone Event [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Registration Payment Arrangement, Settlement Alternatives			Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the Approval Milestone Event), the Company agreed to pay to Intrexon either (i) $3.0 million in cash, or (ii) that number of shares of Common Stock (the Approval Milestone Shares) having a fair market value equaling $3.0 million where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.
Field Expansion Fee [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Registration Payment Arrangement, Settlement Alternatives			The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) $2.0 million in cash for each target in excess of three total that the Company elects, or (ii) that number of shares of Common Stock (the Field Expansion Fee Shares) having a fair market value equaling $2.0 million for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the 30 day period immediately preceding the date of the Field Expansion Fee Closing.
First Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee	303,287
Second Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee	316,438
Third Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Research Agreement Fixed Fee	$ 328,758